… depression low-dose antipsychotic medications, such as risperidone and aripiprazole, for … agreement between doctors and clear guidelines for prescribing medication insufficient access … not receive appropriate medications. This may be because doctors do not …

… patients receiving risperidone.1 "Adjunctive treatment trials in … preference of medication.2 The FDA approved Cobeny … patient response, stringent trial design requirements, and … Drug Approved by FDA Represents First New Treatment Option in Decades. Drug …

… , said: "Adjunctive treatment trials in schizophrenia present significant clinical … as an adjunctive treatment in this trial, the data … between subjects treated with risperidone as a background therapy … to engage with the medical community and regulators …

… Bristol Myers Squibb drug whose landmark FDA approval introduced the … background therapy was not risperidone, a widely prescribed atypical … to engage with the medical community and regulators to … a clinical trial evaluating the drug as a treatment for Alzheimer …

… treatment Cobenfy may have to be scaled down after a trial … to standard atypical antipsychotic medications. There are currently … risperidone as the baseline antipsychotic versus those treated with other drugs … said that adjunctive trials are challenging in …

… Cobenfy as an adjunctive treatment to atypical antipsychotics failed … symptoms. Approved by the FDA to treat schizophrenia in … not on background risperidone. In those non-risperidone patients, Cobenfy … Arise trial marks another blow to BMS’ new drug portfolio …

… the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2 … risperidone). Cobenfy's safety and tolerability profile as an adjunctive treatment … , the FDA approved Cobenfy, an oral medication for schizophrenia … 2 and EMERGENT-3 trials, Cobenfy met its …

… as an adjunctive treatment in this trial, the data … between participants treated with risperidone as a background … (nonrisperidone). "Adjunctive treatment trials in schizophrenia present significant … the US Food and Drug Administration on September 20 …

… on risperidone compared … trial. The company’s Phase 3 trial of Cobenfy as an adjunctive treatment … risperidone compared to those on other antipsychotics, the company said.  The drug … ';s safety and tolerability were consistent with previous trials …

… as an adjunctive treatment in this trial, the data … The US Food and Drug Administration (FDA) approved Cobenfy for … . When patients took risperidone with xanomeline and trospium … as an adjunctive treatment aligned with earlier trials. “These findings …